|
Report Date : |
21.04.2014 |
IDENTIFICATION DETAILS
|
Name : |
ARYSTA LIFE
SCIENCE CORPORATION |
|
|
|
|
Registered Office : |
St Luke’s Tower 38/39F, 8-1 Akashicho
Chuoku Tokyo 104-0044 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.12.2013 |
|
|
|
|
Date of Incorporation : |
April 1977 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Subject is a trading house for importer, exporter and wholesaler of agrochemicals,
pharmaceuticals intermediates & materials, cosmetics raw materials,
health foods, organic chemical intermediates, veterinary products including
veterinary medicines & feed additives |
|
|
|
|
No of Employees : |
100 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Slow but Correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2014
|
Country Name |
Previous Rating (31.12.2013) |
Current Rating (31.03.2014) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderate Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderate High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
Japan ECONOMIC OVERVIEW
In the years following World War II, government-industry
cooperation, a strong work ethic, mastery of high technology, and a comparatively
small defense allocation (1% of GDP) helped Japan develop a technologically
advanced economy. Two notable characteristics of the post-war economy were the
close interlocking structures of manufacturers, suppliers, and distributors,
known as keiretsu, and the guarantee of lifetime employment for a substantial
portion of the urban labor force. Both features are now eroding under the dual
pressures of global competition and domestic demographic change. Japan's
industrial sector is heavily dependent on imported raw materials and fuels. A
small agricultural sector is highly subsidized and protected, with crop yields
among the highest in the world. While self-sufficient in rice production, Japan
imports about 60% of its food on a caloric basis. For three decades, overall
real economic growth had been spectacular - a 10% average in the 1960s, a 5%
average in the 1970s, and a 4% average in the 1980s. Growth slowed markedly in
the 1990s, averaging just 1.7%, largely because of the after effects of inefficient
investment and an asset price bubble in the late 1980s that required a
protracted period of time for firms to reduce excess debt, capital, and labor.
Modest economic growth continued after 2000, but the economy has fallen into
recession three times since 2008. A sharp downturn in business investment and
global demand for Japan's exports in late 2008 pushed Japan into recession.
Government stimulus spending helped the economy recover in late 2009 and 2010,
but the economy contracted again in 2011 as the massive 9.0 magnitude
earthquake and the ensuing tsunami in March disrupted manufacturing. The
economy has largely recovered in the two years since the disaster, but
reconstruction in the Tohoku region has been uneven. Prime Minister Shinzo ABE
has declared the economy his government's top priority; he has overturned his
predecessor's plan to permanently close nuclear power plants and is pursuing an
economic revitalization agenda of fiscal stimulus, monetary easing, and
structural reform. Japan joined the Trans Pacific Partnership negotiations in
2013, a pact that would open Japan's economy to increased foreign competition
and create new export opportunities for Japanese businesses. Measured on a
purchasing power parity (PPP) basis that adjusts for price differences, Japan
in 2013 stood as the fourth-largest economy in the world after second-place
China, which surpassed Japan in 2001, and third-place India, which edged out
Japan in 2012. The new government will continue a longstanding debate on
restructuring the economy and reining in Japan's huge government debt, which is
exceeding 230% of GDP. To help raise government revenue and reduce public debt,
Japan decided in 2013 to gradually increase the consumption tax to a total of
10% by the year 2015. Japan is making progress on ending deflation due to a
weaker yen and higher energy costs, but reliance on exports to drive growth and
an aging, shrinking population pose other major long-term challenges for the
economy.
|
Source : CIA |
ARYSTA LIFE SCIENCE CORPORATION
Arysta Life
Science KK
St Luke’s Tower
38/39F, 8-1 Akashicho Chuoku Tokyo 104-0044 JAPAN
Tel: 03-3547-4500 Fax: 03-3547-4699
URL: www.arystalifescience.com
E-Mail address: info@arystalifescience.com
Subject is a
trading house for importer, exporter and wholesaler of agrochemicals,
pharmaceuticals intermediates
& materials, cosmetics raw materials, health foods, organic chemical
intermediates, veterinary products including veterinary medicines & feed
additives
Sapporo,
Osaka, Fukuoka
Arysta LifeScience N America, Arysta LifeScience Europe, Africa &
Mid East, Arysta LifeScience S America, Arysta LifeScience Haesom Corp (Korea),
Bloomers Growers (New Zealand), Arysta LifeScience Maqyarorszy Kft
(Hungary), Callivoire (Cote D’ivoir) (--group firms)
HISAYA
KOBAYASHI, PRESS Rudorf Van
Houten, rep dir
Christopher
Richards, ch John
Coyle, dir
Alexander
Emery, dir
Yen
Amount: In million Yen, unless
otherwise stated
FINANCES FAIR A/SALES Yen 15,652 M
PAYMENTS slow
but Correct CAPITAL Yen 62,743 M
TREND UP WORTH Yen 29,550 M
STARTED 1977 EMPLOYES 100
TRADING HOUSE SPECIALIZING IN AGROCHEMICALS &
PHARMACEU-TICAL INTERMEDIATES, OWNED BY IEIL JAPAN.
FINANCIAL SITUATION CONSIDERED FAIR
AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS
The subject company was established jointly by Tomen Corp (now Toyota Tsusho Corp) and Nichimen Corp (now Sojitz Corp) in order to advance into new area of life science: agrochemicals and pharmaceutical chemicals. This is a trading house for import, export and wholesale of agrochemicals & pharmaceutical intermediates. Handles a wide range of brands (See OPERATION). Active in overseas expansion. The ownership of the firm changed to IEIL (Industrial Equity Investment Limited) Japan Co, a capital fund investor owned by IEIL Ireland (Permira Funds), in Jun/2008. In Apr 2013 increased the capital to Yen 62,743 million from the previous Yen 59,399 million. Domestic clients include major pharmaceuticals & chemicals mfrs, nationwide.
The sales volume for Dec/2013 fiscal term amounted to Yen 15,652
million, a 23% up from Yen 12,685 million in the previous term. The operations continued in the red to
register Yen 26,973 million recurring loss and Yen 10,938 million net losses,
respectively, compared with Yen 12,017 million recurring loss and Yen 18,108
million net losses, respectively, a year ago.
For the current term ending Dec 2014 the operations are projected to
come back to profitability but still limited to a minimum amount post-taxes, on
a 5% rise in turnover, to Yen 16,500 million.
.
The financial situation is considered FAIR and good for ORDINARY
business engagements.
Date Registered: Apr 1977
Legal Status:
Limited Company (Kabushiki Kaisha)
Authorized:
1,187,986 shares
Issued:
1,187,986 shares
Sum: Yen 59,399 million
Major shareholders (%): IEIL Japan Co Ltd* (Industrial
Equity Investment Ltd) (100)
* Investment fund company & management,
owned by IEIL Ireland (Industrial Equity Investment Ltd), acquired the firm in
Jun/2008.
Nothing
detrimental is known as to the commercial morality of executives.
Activities: A trading house
for import, export and wholesale of agrochemicals, pharma-ceuticals
intermediates & materials, cosmetics raw materials, health foods, organic
chemical intermediates, veterinary products including veterinary medicines
& feed additives, others (--100%).
(Handling Brands)
Select (Registered), Captain, Everest (Registered), Orthene
(Registered), Elevate (Registered),
Clutch, Eminent, Monitor, CaptEvate, Maestro, other.
Clients: [Pharmaceutical
mfrs, chemical firms, wholesalers] Takeda Chemical Ind,
Toyota Tsusho Corp, Sojitz Corp, Sumitomo Chemical, Toyo Green Inc,
Hokko Chemical
Ind, Yonezawa Chemical Co, other.
No. of accounts: 1,000
Domestic areas of activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Takeda Chemical Ind, Nissan Chemical Ind, Kumiai Chemical Ind,
Nippon Soda Co, Yonezawa Chemical Co, JCOM Agri Co, Maruzen Seika, other.
Payment record: Slow but Correct
Location: Business area in
Tokyo. Office premises at the caption
address are leased and maintained satisfactorily.
Bank References:
Aozora Bank (H/O)
MUFG
(Marunouchi)
Relations:
Satisfactory
(In Million Yen)
|
Terms Ending: |
31/12/2014 |
31/12/2013 |
31/12/2012 |
31/12/2011 |
|
|
Annual
Sales |
|
16,500 |
15,652 |
12,685 |
12,545 |
|
Recur.
Profit |
|
0 |
-26,973 |
-12,017 |
-20,400 |
|
Net
Profit |
|
0 |
-10,938 |
-18,108 |
-9,525 |
|
Total
Assets |
|
|
199,194 |
210,248 |
234,220 |
|
Current
Assets |
|
|
13,421 |
8,846 |
9,378 |
|
Current
Liabs |
|
|
13,243 |
23,108 |
25,493 |
|
Net
Worth |
|
|
29,550 |
41,889 |
53,282 |
|
Capital,
Paid-Up |
|
|
62,743 |
59,399 |
59,399 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
5.42 |
23.39 |
1.12 |
-31.00 |
|
|
Current Ratio |
.. |
101.34 |
38.28 |
36.79 |
|
|
N.Worth Ratio |
.. |
14.83 |
19.92 |
22.75 |
|
|
R.Profit/Sales |
0.00 |
-172.33 |
-94.73 |
-162.61 |
|
|
N.Profit/Sales |
0.00 |
-69.88 |
-142.75 |
-75.93 |
|
Note: Forecast (or estimated) for the 31/12/2014 fiscal
term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.38 |
|
UK Pound |
1 |
Rs.101.63 |
|
Euro |
1 |
Rs.83.57 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment record
(10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.